MX9710475A - Utilizacion de al menos un agonista beta-adrenergico como antagonista de sustancia p. - Google Patents

Utilizacion de al menos un agonista beta-adrenergico como antagonista de sustancia p.

Info

Publication number
MX9710475A
MX9710475A MX9710475A MX9710475A MX9710475A MX 9710475 A MX9710475 A MX 9710475A MX 9710475 A MX9710475 A MX 9710475A MX 9710475 A MX9710475 A MX 9710475A MX 9710475 A MX9710475 A MX 9710475A
Authority
MX
Mexico
Prior art keywords
beta
adrenergic agonist
substance
cosmetic
composition
Prior art date
Application number
MX9710475A
Other languages
English (en)
Other versions
MXPA97010475A (es
Inventor
Lionel Breton
Olivier De Lacharriere
Jacques Leclaire
Original Assignee
Oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oreal filed Critical Oreal
Publication of MX9710475A publication Critical patent/MX9710475A/es
Publication of MXPA97010475A publication Critical patent/MXPA97010475A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Abstract

La presente invencion se refiere a la utilizacion de al menos un agonista beta-adrenérgico en una composicion cosmética como antagonista de sustancia P o para la preparacion de una composicion farmacéutica, más particularmente dermatologica, destinada a tratar los desordenes asociados a un exceso de síntesis y/o liberacion de sustancia P. La invencion también se refiere a una composicion cosmética o farmacéutica, para uso topico, que comprende al menos una agonista beta-adrenérgico y un procedimiento de tratamiento cosmético con miras a disminuir el dolor relacionado con un exceso de síntesis y/o liberacion de sustancia P o disminuir el efecto irritante de una composicion cosmética.
MXPA/A/1997/010475A 1995-10-23 1997-12-19 Utilizacion de al menos un agonista beta-adrenergico como antagonista de sustancia p MXPA97010475A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR95/12447 1995-10-23
FR9512447A FR2740040B1 (fr) 1995-10-23 1995-10-23 Utilisation d'au moins un agoniste beta-adrenergique en tant qu'antagoniste de substance p
FR9512447 1995-10-23

Publications (2)

Publication Number Publication Date
MX9710475A true MX9710475A (es) 1998-08-30
MXPA97010475A MXPA97010475A (es) 1998-11-12

Family

ID=

Also Published As

Publication number Publication date
EP0769293B1 (fr) 1999-08-11
NO976143D0 (no) 1997-12-30
DE69603681T2 (de) 1999-11-25
WO1997015281A1 (fr) 1997-05-01
FR2740040A1 (fr) 1997-04-25
EP0769293A3 (fr) 1997-05-02
FR2740040B1 (fr) 1997-12-05
US6267972B1 (en) 2001-07-31
NO312273B1 (no) 2002-04-22
HUP9900511A3 (en) 2000-09-28
JP2000503628A (ja) 2000-03-28
PL324924A1 (en) 1998-06-22
CA2222311A1 (fr) 1997-05-01
DK0769293T3 (da) 1999-12-06
US5958432A (en) 1999-09-28
NO976143L (no) 1998-06-03
PL186366B1 (pl) 2003-12-31
EP0769293A2 (fr) 1997-04-23
HUP9900511A2 (hu) 1999-07-28
BR9611302A (pt) 1999-03-30
CA2222311C (fr) 2006-11-28
RU2169552C2 (ru) 2001-06-27
JP3636473B2 (ja) 2005-04-06
DE69603681D1 (de) 1999-09-16
AR004052A1 (es) 1998-09-30

Similar Documents

Publication Publication Date Title
EP1014996A4 (en) SACCHARIDE COMPOSITIONS AND METHODS FOR SPECIFIC TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AMYLOIDOSIS
ZA95741B (en) Therapeutic agents
HUP9800033A3 (en) Compositions for the treatment of dermatological disorders and methods for their use
ZA938421B (en) Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders
HUP9801599A3 (en) Use of imidazolin derivatives having alfa1l agonist effect for producing pharmaceutical compositions for treatment of incontinence, novel imidazolin derivatives and process for producing them
MY119403A (en) Novel compounds with analgesic effect.
MY132705A (en) Novel compounds with analgesic effect
GEP20022783B (en) Method of Preventing and Delaying Onset of Alzheimer's Disease and Composition Therefor
HU9602522D0 (en) Heterocyclic compounds, their preparation and use
ITMI950575A0 (it) Preparati igienici e cosmetici per prevenire e trattare malattie della pelle nonche' procedimento per il loro ottenimento
RU95103892A (ru) Композиция топического нанесения для стимулирования роста волос и/или замедления их выпадения, способ косметического лечения волос, применение производного альфа -пирона для получения композиции
UA35611C2 (uk) Композиція місцевого застосування для інгібування росту волос у ссавців, спосіб із її використанням та композиція місцевого застосування для доставки водорозчинного фармакологічного засобу до шкіри
DE68912195D1 (de) Verwendung von Pyrrolicloncarbonsäurealkylestern zur Herstellung eines Arzneimittels zur Behandlung von Ichtyosis.
AR004052A1 (es) Una composición cosmética o farmacéutica que comprende un agonista beta-adrenergico
EP0214254A1 (en) MELATONIN COMPOSITIONS AND USES THEREOF.
ZA898605B (en) Compositions for topical treatment of skin diseases
AU7029298A (en) Cosmetic body-care preparation and process for preparing the same
AU691336B2 (en) Use of 2,4-diamino pyrimidine 3-oxide or a salt thereof for treating collagen maturation and structuring disorders
KR970703142A (ko) 신전성 선조를 치료하기 위해 알파 히드록시산을 도포시키는 방법(applying alpha hydroxy acids for striae distensae)
CA2015585A1 (en) Method and compositions for treatment of mast cell-mediated dermatologic disorders
NZ268039A (en) Use of efaroxan in treating parkinson's disease
AP2000002004A0 (en) Method of treatment for dermatological disorders and compositions therefor.
DE69825322D1 (de) Topische carbamazepin-formulierungen und deren verwendung
HU9700079D0 (en) Topical compositions for the treatment of skin disease
IT1288708B1 (it) Composizione farmaceutica comprendente trometamina per il trattamento per via topica dell'acne vulgaris.

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees